DYRK1A and osteosarcoma: Individual siRNAs designed to target a gene (as we have shown in the case of DYRK1A dependency in RB1 null cell lines) or small molecule inhibitors (as we have shown for the FGFR sensitivity of osteosarcoma cell lines) might be used as a form of validation.